These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30177280)

  • 1. Adverse reactions related to brentuximab vedotin use: A real-life retrospective study.
    Clarivet B; Vincent L; Vergely L; Bres V; Foglia K; Cartron G; Hillaire-Buys D; Faillie JL
    Therapie; 2019 Jun; 74(3):343-346. PubMed ID: 30177280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
    Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
    Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis.
    Gao S; Zhang M; Wu K; Zhu J; He Z; Li J; Chen C; Qiu K; Yu X; Wu J
    Expert Opin Drug Saf; 2020 May; 19(5):617-623. PubMed ID: 31955620
    [No Abstract]   [Full Text] [Related]  

  • 4. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
    Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
    JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
    Tien FM; Tsai CH; Liu JH; Lin CT
    J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
    Matthys A; Bardel B; Le Bras F; Créange A; Nordine T; Gounot R; Ingen-Housz-Oro S; Carvalho M; Lefaucheur JP; Haioun C; Planté-Bordeneuve V; Gendre T
    Eur J Neurol; 2024 Jul; 31(7):e16285. PubMed ID: 38511878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.
    Nanni L; Pellegrini C; Stefoni V; Argnani L; Cavo M; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e595-e596. PubMed ID: 31543370
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.
    Sharman JP; Wheler JJ; Einhorn L; Dowlati A; Shapiro GI; Hilton J; Burke JM; Siddiqi T; Whiting N; Jalal SI
    Invest New Drugs; 2019 Aug; 37(4):738-747. PubMed ID: 30993587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
    Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
    Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
    Poston JN; Fromm JR; Rasmussen HA; Shustov AR; Libby EN; Smith SD; Gooley T; Gopal AK
    Br J Haematol; 2019 Jul; 186(1):159-162. PubMed ID: 30592026
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
    Milunović V; Mišura Jakobac K; Kursar M; Mandac Rogulj I; Ostojić Kolonić S
    Eur J Haematol; 2019 Sep; 103(3):145-151. PubMed ID: 31166030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
    Gotlib J; Baird JH; George TI; Langford C; Reyes I; Abuel J; Perkins C; Schroeder K; Bose P; Verstovsek S
    Blood Adv; 2019 Aug; 3(15):2264-2271. PubMed ID: 31350306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
    Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
    Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy.
    Mariotto S; Tecchio C; Sorio M; Bertolasi L; Turatti M; Tozzi MC; Benedetti F; Cavaletti G; Monaco S; Ferrari S
    Leuk Lymphoma; 2019 Nov; 60(11):2806-2809. PubMed ID: 31057013
    [No Abstract]   [Full Text] [Related]  

  • 15. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute neurologic deterioration in a patient with asymptomatic Charcot-Marie-Tooth disease following three doses of Brentuximab-Vedotin.
    de la Nuez Melián H; Luzardo Henríquez H; Suárez Cabrera A; Stuckey R; Gómez-Casares MT
    Leuk Lymphoma; 2024 Oct; 65(10):1532-1534. PubMed ID: 38829355
    [No Abstract]   [Full Text] [Related]  

  • 17. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Remission by Brentuximab Vedotin for Non-mediastinal Gray Zone Lymphoma Refractory to Autologous Stem Cell Transplantation.
    Ebisawa K; Masamoto Y; Koya J; Shimura A; Shinozaki-Ushiku A; Toyama K; Nakazaki K; Kurokawa M
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e602-e604. PubMed ID: 31551171
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
    Shao C; Liu J; Zhou W; Raut MK; Monberg M; Cao X; Ricart AD; Balakumaran A
    Leuk Lymphoma; 2019 Apr; 60(4):947-954. PubMed ID: 30234407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
    Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
    Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.